Showing 1 posts of 1 posts found.
Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
MHRA awards Innovation Passports to liver cancer and dementia medicines
Scottish NHS hospital adopts light-activated therapy to reduce surgical infections
Manchester launches nurse-led clinic to improve kidney transplant outcomes
Androlabs and Majorelle expand testosterone therapy into France